Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | GRM6 | O15303 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1194383 | 0.81 | ALDH1A1 (0.58) | KDM4EALDH1A1SMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL15872816 | 0.81 | NPSR1 (0.50) | NPSR1KDM4EALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL16417686 | 0.80 | NPSR1 (0.54) | NPSR1KDM4EALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL30862551 | 0.79 | NPSR1 (0.48) | NPSR1KDM4EALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL12661719 | 0.78 | PDPK1 (0.38) | KDM4EALDH1A1SMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL2829075 | 0.78 | SMN1; SMN2 (0.38) | ALDH1A1SMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL7454034 | 0.77 | ALDH1A1 (0.37) | NPSR1KDM4EALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL2829789 | 0.77 | NPSR1 (0.50) | NPSR1KDM4EALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL275767 | 0.77 | NPSR1 (0.50) | NPSR1KDM4EALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL12228844 | 0.77 | NPSR1 (0.50) | NPSR1KDM4EALDH1A1SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024233605-A1 | COMPOUNDS AND THEIR USE AGAINST CANCER | TANGO THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-3523305-B1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2021-12-08 | — | — | EP | disclosed |
| US-10836770-B2 | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or INF alpha responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-11-17 | — | — | US | disclosed |
| US-20190225620-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2019-07-25 | — | — | US | disclosed |
| WO-2018067432-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-04-12 | — | — | WO | disclosed |
| EP-1844044-B1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-07-21 | — | — | EP | disclosed |
| US-7678815-B2 | Thiazole-4-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| EP-1844044-A1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-10-17 | — | — | EP | disclosed |
| US-20060160857-A1 | Thiazole-4-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. | 2006-07-20 | — | — | US | disclosed |
| WO-2006074884-A1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225620-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | TYK2, IL2, IFNAR1 | NPSR1 3910/4885KDM4E 2621/4885ALDH1A1 3821/4885 |
| US-20060160857-A1 | Thiazole-4-carboxyamide derivatives | GRM1, GRM2, GRIA4 | NPSR1 173/4885KDM4E 1059/4885ALDH1A1 913/4885 |
| US-10836770-B2 | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or INF alpha responses | TYK2, IL2, IFNAR1 | NPSR1 3830/4885KDM4E 3599/4885ALDH1A1 3818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.